nach oben

The European Journal of Health Economics

Erschienen in:

01.02.2012 | Original Paper

Cost-effectiveness model for a specific mixture of prebiotics in The Netherlands

verfasst von: I. Lenoir-Wijnkoop, W. M. C. van Aalderen, G. Boehm, D. Klaassen, A. B. Sprikkelman, M. J. C. Nuijten

Erschienen in: The European Journal of Health Economics | Ausgabe 1/2012

Einloggen, um Zugang zu erhalten

Abstract

The objective of this study was to assess the cost-effectiveness of the use of prebiotics for the primary prevention of atopic dermatitis in The Netherlands. A model was constructed using decision analytical techniques. The model was developed to estimate the health economic impact of prebiotic preventive disease management of atopic dermatitis. Data sources used include published literature, clinical trials and official price/tariff lists and national population statistics. The comparator was no supplementation with prebiotics. The primary perspective for conducting the economic evaluation was based on the situation in The Netherlands in 2009. The results show that the use of prebiotics infant formula (IMMUNOFORTIS^®) leads to an additional cost of € 51 and an increase in Quality Adjusted Life Years (QALY) of 0.108, when compared with no prebiotics. Consequently, the use of infant formula with a specific mixture of prebiotics results in an incremental cost-effectiveness ratio (ICER) of € 472. The sensitivity analyses show that the ICER remains in all analyses far below the threshold of € 20,000/QALY.

Conclusion

This study shows that the favourable health benefit of the use of a specific mixture of prebiotics results in positive short- and long-term health economic benefits. In addition, this study demonstrates that the use of infant formula with a specific mixture of prebiotics is a highly cost-effective way of preventing atopic dermatitis in The Netherlands.

Leung, D.Y., Bieber, T.: Atopic dermatitis. Lancet 361, 151–160 (2003)PubMedCrossRef

Kunz, B., Oranje, A.P., Labreze, L., et al.: Clinical validation and guidelines for the SCORAD index: consensus report of the European task force on atopic dermatitis. Dermatology 195, 10–19 (1997)

Sturgill, S., Bernard, L.A.: Atopic dermatitis update. Curr. Opin. Pediatr. 16, 396–401 (2004)PubMedCrossRef

Levy, R.M., Gelfand, J.M., Yan, A.C.: The epidemiology of atopic dermatitis. Clin. Dermatol. 21, 109–115 (2003)PubMedCrossRef

Williams, H.C.: Epidemiology of atopic dermatitis. Clin. Exp. Dermatol. 25, 522–529 (2000)PubMedCrossRef

The International Study of Asthma and Allergies in Childhood (ISAAC) Steering Committee.: Worldwide variation in prevalence of symptoms of asthma, allergic rhinoconjunctivitis, and atopic eczema. Lancet 351, 1225–1232 (1998)

Schultz-Larsen, F.: Atopic dermatitis: a genetic-epidemiologic study in a population-based twin sample. J. Am. Acad. Dermatol. 28, 719–723 (1993)PubMedCrossRef

Butland, B.K., Strachan, D.P., Lewis, S., Bynner, J., Butler, N., Britton, J.: Investigation into the increase in hay fever and eczema at age 16 observed between the 1958 and 1970 British birth cohorts. BMJ 315, 717–721 (1997)PubMedCrossRef

Reitamo, S., Remitz, A., Haahtela, T.: Hit early and hit hard in atopic dermatitis and not only in asthma. Allergy 64, 503–504 (2009)

10.

Carroll, C.L., Balkrishnan, R., Feldman, S.R., et al.: The burden of atopic dermatitis: impact on the patient, family, and society. Pediatr. Dermatol. 22, 192–199 (2005)

11.

Schmid-Ott, G., Kuensebeck, H.W., Jaeger, B., et al.: Validity study for the stigmatization experience in atopic dermatitis and psoriatic patients. Acta. Derm. Venereol. 79, 443–447 (1999)

12.

Ben-Gashir, M.A.: Relationship between quality of life and disease severity in atopic dermatitis/eczema syndrome during childhood. Curr. Opin. Allergy Clin. Immunol. 3, 369–373 (2003)PubMedCrossRef

13.

Finlay, A.Y., Khan, G.K.: Dermatology life quality index (DLQI)–a simple practical measure for routine clinical use. Clin. Exp. Dermatol. 19, 210–216 (1994)PubMedCrossRef

14.

Lewis-Jones, M.S., Finlay, A.Y.: The children’s dermatology life quality index (CDLQI): initial validation and practical use. Br. J. Dermatol. 32, 942–949 (1995)

15.

Abeni, D., Picardi, A., Pasquini, P., et al.: Further evidence of the validity and reliability of the Skindex-29: an Italian study on 2,242 dermatological outpatients. Dermatology 204, 43–49 (2002)

16.

Absolon, C.M., Cottrell, D., Eldridge, S.M., et al.: Psychological disturbance in atopic eczema: the extent of the problem in school-aged children. Br. J. Dermatol. 137, 241–245 (1997)

17.

Beattie, P.E., Lewis-Jones, M.S.: A comparative study of impairment of quality of life in children with skin disease and children with other chronic childhood diseases. Br. J. Dermatol. 155, 145–151 (2006)PubMedCrossRef

18.

Ben-Gashir, M.A., Seed, P.T., Hay, R.J.: Quality of life and disease severity are correlated in children with atopic dermatitis. Br. J. Dermatol. 150, 284–290 (2004)PubMedCrossRef

19.

Chamlin, S.L., Cella, D., Frieden, I.J., et al.: Development of the childhood atopic dermatitis impact scale: initial validation of a quality-of-life measure for young children with atopic dermatitis and their families. J. Invest. Dermatol. 125, 1106–1111 (2005)

20.

Holm, E.A., Wulf, H.C., Stegmann, H., et al.: Life quality assessment among patients with atopic eczema. Br. J. Dermatol. 154, 719–725 (2006)

21.

Kiebert, G., Sorensen, S.V., Revicki, D., et al.: Atopic dermatitis is associated with a decrement in health-related quality of life. Int. J. Dermatol. 41, 151–158 (2002)

22.

Lewis-Jones, S.: Measuring the burden of atopic eczema in young children and the family unit. J. Invest. Dermatol. 125, viii (2005)

23.

Lundberg, L., Johannesson, M., Silverdahl, M., et al.: Health related quality of life in patients with psoriasis and atopic dermatitis measured with SF-36, DLQI and a subjective measure of disease activity. Acta. Derm. Venereol. 80, 430–434 (2000)

24.

Sampogna, F., Picardi, A., Chren, M.M. et al.: Association between poorer quality of life and psychiatric morbidity in patients with different dermatological conditions. Psychosom. Med. 66, 620–624 (2004)

25.

Wittkowski, A., Richards, H.L., Griffiths, C.E. et al.: The impact of psychological and clinical factors on quality of life in individuals with atopic dermatitis. J. Psychosom. Res. 57, 195–200 (2004)

26.

Brenninkmeijer, E.E.A., Legierse, C.M., Sillevis Smitt, J.H., Last, B.F., Grootenhuis, M.A., Bos, J.D.: The course of life of patients with childhood atopic dermatitis. Allergy 64, 840–848 (2009)

27.

Wille, N., Badia, X., Bonsel, G., Burström, K., Cavrini, G., Devlin, N., Egmar, A.C., Greiner, W., Gusi, N., Herdman, M., Jelsma, J., Kind, P., Scalone, L., Ravens-Sieberer, U.: Development of the EQ-5D-Y: a child-friendly version of the EQ-5D. Qual. Life Res. 19(6), 875–886 (2010)PubMedCrossRef

28.

Rhodes, H.L.: Early life risk factors for adult asthma: a birth cohort study of subjects at risk. J. Allergy Clin. Immunol. 108, 720–725 (2001)PubMedCrossRef

29.

Kulig, M., Bergmann, R., Klettke, U., Wahn, V., Tacke, U., Wahn, U., et al.: Natural course of sensitization to food and inhalant allergens during the first 6 years of life. J. Allergy Clin. Immunol. 103, 1173–1179 (1999)

30.

Spergel, J.H., Paller, A.S.: Atopic dermatitis and the atopic march. J. Allergy Clin. Immunol. 112, S118–S127 (2003)PubMedCrossRef

31.

Liu, A.H., Martinez, F.D., Taussig, L.M.: Natural history of allergic diseases and asthma. In: Leung, D.Y.M., Sampson, H.A., Geha, R.S., Szefler, S.J. (eds.) Pediatric Allergy: Principles and Practice, pp. 10–22. Elsevier, Philadelphia (2003)

32.

Bergmann, R.L., Edenharter, G., Bergmann, K.E., Forster, J., et al.: Atopic dermatitis in early infancy predicts allergic airway disease at 5 years. Clin. Exp. Allergy 28, 965–970 (1998)

33.

Gustafsson, D., Sjoberg, O., Foucard, T.: Development of allergies and asthma in infants and young children with atopic dermatitis—a prospective followup to 7 years of age. Allergy 55, 240–245 (2000)PubMedCrossRef

34.

Van der Hulst, A.E., Klip, H., Brand, P.L.: Risk of developing asthma in young children with atopic eczema: a systematic review. J. Allergy Clin. Immunol. 120, 565–569 (2007)

35.

Hanifin, J.M., Reed, M.L.: A population-based survey of eczema prevalence in the United States. Dermatitis 18, 82–91 (2007)PubMedCrossRef

36.

Martin Fernandez-Mayoralas, D., Martin Caballero, J.M., Garcia-Marcos Alvarez, L.: Association between atopic dermatitis, allergic rhinitis and asthma in schoolchildren aged 13–14 years old. An. Pediatr. (Barc) 60, 236–242 (2004)

37.

Hakansson, K., Thomsen, SF., Ulrik, C.S., Porsbjerg, C., et al.: Increase in the prevalence of rhinitis among Danish children from 1986 to 2001. Pediatr. Allergy Immunol. 18, 154–159 (2007)

38.

Simpson, E.L., Hanifin, J.M.: Atopic dermatitis. J. Am. Acad. Dermatol. 53, 115–128 (2005)PubMedCrossRef

39.

Mancini, A.J., Kaulback, K., Chamlin, S.L.: The socioeconomic impact of atopic dermatitis in the United States: a systematic review. Pediatr. Dermatol. 25, 1–6 (2008)PubMedCrossRef

40.

Kalliomäki, M., Salminen, S., Poussa, T., Arvilommi, H., Isolauri, E.: Probiotics and prevention of atopic disease: 4-year follow-up of a randomized placebo-controlled trial. Lancet 361, 1869–1871 (2003)PubMedCrossRef

41.

Kalliomäki, M., Salminen, S., Poussa, T., Isolauri, E.: Probiotics during the first 7 years of life: a cumulative risk reduction of eczema in a randomized, placebo-controlled trial. J. Allergy Clin. Immunol. 119, 1019–1021 (2007)PubMedCrossRef

42.

Wickens, K., Black, P.N., Stanley, T.V., Mitchell, E., et al.: A differential effect of 2 probiotics in the prevention of eczema and atopy: a double-blind, randomized, placebo-controlled trial. J. Allergy Clin. Immunol. 122, 788–794 (2008)

43.

Moro, G., Arslanoglu, S., Stahl, B., Jelinek, J., Wahn, U., Boehm, G.: A mixture of prebiotic oligosaccharides reduces the incidence of atopic dermatitis durig the first six months of age. Arch. Dis. Child. 91, 814–819 (2006)PubMedCrossRef

44.

Arslanoglu, S., Moro, G., Schmitt, J., Tandoi, L., Rizzardi, S., Boehm, G.: Early dietary intervention with a mixture of prebiotic oligosaccharides reduces the incidence of allergic manifestations and infections during the first two years of life. J. Nutr. 138, 1091–1095 (2008)

45.

Weinstein, M.C., Fineberg, H.V.: Clinical Decision Analysis, pp. 228–265. WB Saunders Co, Philadelphia, PA (1980)

46.

Lenoir-Wijnkoop, I., Dapoigny, M., Dubois, D., van Ganse, E., Gutiérrez-Ibarluzea, I., Hutton, J., Jones, P., Mittendorf, T., Poley, M.J., Salminen, S., Nuijten, M.J.: Nutrition economics—characterising the economic and health impact of nutrition. Br. J. Nutr. 1–9 (2010). doi:10.1017/s0007114510003041

47.

Nuijten, M.J.C., Al, M., Rutten, F.: In search for more confidence in health economic modelling (thesis) (2003)

48.

Richtlijnen voor farmaco-economisch onderzoek. Geactualiseerde versie (April 2006). College voor zorgverzekeringen. Diemen. Maart 2006

49.

RIVM. www.rivm.nl/vtv/object_document/o4663n18082.html

50.

Lowe, A.J., Abramson, M.J., Hosking, C.S., Carlin, J.B., et al.: The temporal sequence of allergic sensitization and onset of infantile eczema. Clin. Exp. Allergy 37, 536–542 (2007)

51.

Poole, D., Chambers, C., Sidhu, M.K., Currie, C.J.: Health-related utility among adults with atopic dermatitis treated with tacrolimus ointment as maintenance therapy over the long term: findings from the Protopic_CONTROL study. Br. J. Dermatol. 161, 1335–1340 (2009)

52.

Greenough, A., Alexander, J., Burgess, S., Bytham, J., Chetcuti, P.A., Hagan, J., Lenney, W., Melville, S., Shaw, N.J., Boorman, J., Coles, S., Turner, J., Pang, F.: Health care utilisation of prematurely born, preschool children related to hospitalisation for RSV infection. Arch. Dis. Child. 89(7), 673–678 (2004)PubMedCrossRef

53.

Malhotra, A., Krilov, L.: Influenza and respiratory syncytial virus.: Update on infection, management and prevention. Pediatr. Clin. North Am. 47, 353–372 (2000)PubMedCrossRef

54.

Welliver, R., Duffy, L.: The relationship of RSV-specific immunoglobulin E antibody responses in infancy, recurrent wheezing and pulmonary functions at age 7–8 years. Pediatr. Pulmonol. 15, 19–27 (1993)PubMedCrossRef

55.

Su, J.C., Kemp, A.S., Varigos, G.A., Nolan, T.M.: Atopic eczema: its impact on the family and financial cost. Arch. Dis. Child. 76, 159–162 (1997)PubMedCrossRef

56.

Hoogendoorn, E.J.I., Feenstra, T.L., Rutten-van Mölken, M.P.M.H.: Inventarisatie van het gebruik en de kosten van zorg voor astma en COPD in Nederland. RIVM rapport 260604001 (2004)

57.

Reid, P., Lewis-Jones, M.S.: Sleep difficulties and their management in preschoolers with atopic eczema. Clin. Exp. Dermatol. 20, 38–41 (1995)PubMedCrossRef

58.

Kemp, A.S.: Atopic eczema: its social and financial costs. J. Paediatr. Child Health 35, 229–231 (1999)

59.

Lenny W.: The burden of pediatric asthma. Pediatr. Pulmonol. Suppl. 15, 13–16 (1997)

60.

http://www.cbs.nl/nl-NL/menu/themas/bevolking/cijfers/extra/piramide-fx.htm

Titel: Cost-effectiveness model for a specific mixture of prebiotics in The Netherlands
verfasst von: I. Lenoir-Wijnkoop
W. M. C. van Aalderen
G. Boehm
D. Klaassen
A. B. Sprikkelman
M. J. C. Nuijten
Publikationsdatum: 01.02.2012
Verlag: Springer-Verlag
Erschienen in: The European Journal of Health Economics / Ausgabe 1/2012
Print ISSN: 1618-7598
Elektronische ISSN: 1618-7601
DOI: https://doi.org/10.1007/s10198-010-0289-4

Springer Medizin

Abstract

Conclusion

Bitte loggen Sie sich ein, um Zugang zu diesem Inhalt zu erhalten

Weitere Artikel der Ausgabe 1/2012

Do smoke-free laws affect revenues in pubs and restaurants?

Is it time to reconsider the role of patient co-payments for pharmaceuticals in Europe?

Pharmacoeconomic evaluation of tiotropium bromide in the long-term treatment of chronic obstructive pulmonary disease (COPD) in Italy

The convergence of health care financing structures: empirical evidence from OECD-countries

The cost of multiple sclerosis in Norway

Comparing the sensitivity of EQ-5D, SF-6D and 15D utilities to the specific effect of diabetic complications